Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · 单克隆抗体

什么是 bevacizumab?

bevacizumab 是一种单克隆抗体,由Mylan研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Abevmy, bevacizumab, Biocon, Krabeva
公司Mylan
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点:

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedEye (London, England)2026-11-19

Incidence and visual outcomes of post-intravitreal injection endophthalmitis: a single-centre analysis of 224,397 injections.

Kayikci Mahmutoglu Gulce G, Simsek Metehan M, Cevik Sadik Gorkem SG, Arici Murat M et al.

Post-injection endophthalmitis (PIE) is a rare, vision-threatening complication of intravitreal injections (IVIs). As IVI volumes rise globally, optimising prevention and management is crucial. This study evaluated PIE incidence, risk factors, microbiology, and outcomes over ten years. A retrospective cohort study of 224,397 IVIs. We analysed demographics, agent type, and preparation (pre-filled syringe [PFS] vs. manual aliquoting). Overall endophthalmitis incidence was 0.029% (n = 65), and 0.026% for anti-VEGFs. PFS-ranibizumab had the lowest incidence (0.014%) and was significantly safer than manually prepared bevacizumab (0.039%; OR: 2.74 [95% CI: 1.36-5.55], p = 0.003); vial-sourced aflibercept (0.027%) was intermediate and not statistically distinguishable from either. Culture positivity was 33.8% (n = 22), predominantly Gram-positive (81.8%), with Staphylococcus epidermidis being the most common (45.5%). In univariate analysis, culture positivity was the sole predictor of worse final visual acuity (VA) (p = 0.030), though limited by small sample sizes. Median VA worsened from 0.61 logMAR at baseline to 2.10 logMAR at presentation, recovering to 1.80 logMAR at final visit (p < 0.001). Among cases initially treated with tap and intravitreal antibiotics (TAI), 60% (21/35) required subsequent vitrectomy (PPV). No baseline clinical parameters predicted TAI success or PPV requirement (all p > 0.05). Dexamethasone implants, with their larger applicator, carried the highest risk. Among anti-VEGFs, PFS ranibizumab demonstrated the most favourable safety profile, with the lowest incidence of PIE. Manual immediate-use bevacizumab aliquoting is a safe, cost-effective alternative in resource-limited settings. In univariate analysis, culture positivity emerged as a negative prognostic factor, though this finding is limited by small sample sizes. Given unpredictable TAI responses, aggressive monitoring and a low PPV threshold are essential.

PMID 43052414
阅读全文 →
PubMedClinical journal of gastroenterology2026-11-18

Salvage surgery for intratumoral regrowth after a marked response to atezolizumab plus bevacizumab in borderline resectable hepatocellular carcinoma.

Ochi Atsuhiko A, Tani Keigo K, Itobayashi Ei E, Sasaki Naomichi N et al.

The advent of immunotherapy, particularly the combination of atezolizumab plus bevacizumab (Atez + Bev), has improved outcomes in patients with unresectable hepatocellular carcinoma (HCC). Its high antitumor efficacy has enabled an increasing number of patients to undergo conversion therapy. We report a case of massive, borderline resectable HCC with advanced portal vein tumor thrombus (PVTT), in which hepatectomy was performed for intratumoral regrowth after an initial response to Atez + Bev. After six cycles, the tumor, including the PVTT, showed marked regression, and treatment was continued. After 12 cycles, intratumoral regrowth emerged within the previously regressed tumor. Right hepatectomy was performed, achieving R0 resection. The patient received no postoperative systemic therapy and has remained recurrence-free for three years. Even when the optimal timing for conversion surgery during Atez + Bev therapy is missed and intratumoral regrowth occurs, salvage surgery may still offer the potential for long-term survival, depending on the pattern and location of regrowth.

PMID 43050092
阅读全文 →
PubMedInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026-11-18

Fuzuloparib plus apatinib maintenance in patients with platinum-sensitive recurrent ovarian cancer previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance (FLASH): an exploratory phase II trial.

Lv Mengmeng M, Lu Jin J, Ma Xuejiao X, Shen Yang Y et al.

Fuzuloparib, a poly(adenosine diphosphate-ribose) polymerase inhibitor, has demonstrated survival benefits as maintenance therapy in poly(adenosine diphosphate-ribose) polymerase inhibitor-naïve patients with platinum-sensitive recurrent ovarian cancer. This study evaluated the efficacy and safety of fuzuloparib combined with apatinib in patients with platinum-sensitive recurrent ovarian cancer who were previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance. This single-arm, exploratory phase II trial enrolled adults with ovarian cancer who had received first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance and had responded to recent platinum-based chemotherapy. Participants received oral fuzuloparib (100 mg twice daily) plus apatinib (250 mg once daily) until disease progression, unacceptable toxicity, or withdrawal. The primary endpoint was progression-free survival. Between April 2022 and January 2024, 28 patients (median age: 54.5 years) were enrolled. The median time since the most recent poly(adenosine diphosphate-ribose) polymerase inhibitor treatment was 5.4 months (interquartile range; 4.4-6.7). Bevacizumab was used in the most recent chemotherapy regimen in 60.7% of patients, and 85.7% achieved a partial response to the recent chemotherapy. With a median follow-up of 9.9 months, the median progression-free survival was 4.86 months (95% confidence interval 3.38 to 9.40). The median progression-free survival was 5.29 months (95% confidence interval 1.05 to 9.40) in patients who received bevacizumab and 4.53 months (95% confidence interval 2.4 to not reached) in those who did not. The median overall survival was 15.87 months (95% confidence interval 15.54 to not reached), although this estimate remained immature because of the limited number of observed events. Grade 3 or 4 adverse events occurred in 32.1% of patients, most commonly decreased platelet count (14.3%) and anemia (10.7%). No cases of myelodysplastic syndrome, acute myeloid leukemia, or treatment-related deaths were observed. This study is the first, to our knowledge, to evaluate dual oral therapy with fuzuloparib and apatinib in patients with platinum-sensitive recurrent ovarian cancer who were previously treated with first-line poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance. Preliminary findings suggest anti-tumor activity with manageable toxicity, warranting further investigation. chictr.org.cn: ChiCTR2200059352.

PMID 43052119
阅读全文 →
PubMedJournal of Alzheimer's disease : JAD2026-11-18

Network proximity-based drug repurposing identifies anti-inflammatory therapies for Alzheimer's disease.

Cammann Davis D, Cummings Jeffrey L JL, Zhou Yadi Y, Cheng Feixiong F et al.

BackgroundNeuroinflammation is implicated as a driver of cellular dysfunction in Alzheimer's disease (AD), yet there are currently no FDA-approved drugs to treat this pathology. Network models of protein-protein interactions (PPI) show promise in identifying drug mechanisms of action targeted towards disease pathologies.ObjectiveWe sought to identify repurposable drugs to treat neuroinflammation by screening drug targets on an extensive PPI network against proteins involved in AD neuroinflammatory pathways.MethodsWe identified 133 immune system pathway genes from AD genomic and transcriptomic studies, creating a network module on a human PPI network. We assessed the network proximity of this module to drug target modules across three screenings: inflammation-targeted drugs with a negative AD clinical trial, repurposed compounds in AD clinical trials as of 2025, and 1700 FDA-approved compounds. Drugs were prioritized if they had Z-scored proximity less than -2.0, a false-discovery rate corrected p-value less than 0.05, and evidence in transgenic mouse models or AD clinical trials.ResultsWe found that anti-inflammatory drugs with negative AD clinical trials had low proximity to AD-neuroinflammatory targets, while the phase 2 drug baricitinib was significantly proximal. Screening 1700 FDA-approved compounds, we found 15 with significant network proximity to AD-immune system targets. Notably, cabozantinib, plerixafor, and bevacizumab had positive biomarker effects in AD mouse models.ConclusionsWe provide an in-silico line of evidence for several repurposable drugs to be tested further in-vitro and in-vivo studies of AD.

PMID 43048891
阅读全文 →
PubMedNeuro-oncology practice2026-11-18

Efficacy of vorasidenib for patients with IDH-mutant glioma previously treated with ivosidenib.

Schultz Sydney E SE, Barreto Jason N JN, Mead-Harvey Carolyn C, Caron Samantha J SJ et al.

Isocitrate dehydrogenase-1 (IDH-1) inhibitor ivosidenib and dual-IDH1/2 inhibitor vorasidenib have demonstrated clinical activity in the treatment of IDH-mutant gliomas. We evaluated the efficacy of vorasidenib in patients with prior exposure to ivosidenib. Retrospective review of patients with IDH-mutant glioma treated with vorasidenib who had prior treatment with ivosidenib. Previous treatments, radiographic response, and adverse events were collected and analyzed descriptively. Twenty-nine patients (median age 42, 34% female) were evaluated. Tumor types included IDH-mutant astrocytoma (grade 2 n = 9, 31%; grade 3 n = 3, 10%; grade 4 n = 3, 10%) and oligodendroglioma (grade 2 n = 10, 34%; grade 3 n = 4, 14%). Treatments received prior to ivosidenib included surgical resection (n = 23, 79%), radiation (n = 16, 55%), temozolomide (n = 15, 52%), procarbazine, lomustine, vincristine (PCV, n = 2, 7%), bevacizumab (n = 3, 10%), lomustine (n = 2, 7%), and pembrolizumab (n = 1, 3%). Four patients received additional treatment in between ivosidenib and vorasidenib treatment.Ten of 16 (63%) patients who experienced disease progression on ivosidenib achieved stable disease and remain on vorasidenib, while 6 (37%) had continued progression. Eleven patients with stable disease on ivosidenib transitioned to vorasidenib following FDA approval and remained without progression. Two patients who transitioned to vorasidenib due to ivosidenib-related adverse effects (diarrhea and fatigue) experienced symptom resolution and maintained disease stability. Vorasidenib demonstrated clinical efficacy in patients with IDH-mutant gliomas previously treated with ivosidenib. Notably, stable patients who transitioned maintained disease stability, while some of those with progressive disease achieved stabilization with vorasidenib. These findings support vorasidenib as a viable therapeutic option following ivosidenib exposure.

PMID 43047530
阅读全文 →
PubMedAnalytical chemistry2026-11-18

Fast Intrinsic NMR Reporters of Molecular Changes Correlating with Biological Activity in Stressed Therapeutic Monoclonal Antibodies.

Gairí Margarida M, González M Teresa MT, Beaumont Victor V, Liu Lucy L LL et al.

The biological activity and stability of monoclonal antibodies (mAbs) can be potentially compromised by chemical and conformational changes and assessing the structural integrity of mAbs is therefore a critical task in biopharmaceutical development. Monitoring higher-order structure (HOS) in formulated mAbs remains a critical analytical challenge. Here, we present an integrated nuclear magnetic resonance (NMR)-based framework for characterizing stress-induced modifications in therapeutic antibodies and correlating them with functional activity. In this study, adalimumab, trastuzumab and bevacizumab in their respective formulations were subjected to controlled light and thermal stress alongside matched unstressed controls, and analyzed using 1D and 2D NMR spectroscopy, liquid chromatography/mass spectrometry (LC/MS), mass photometry, and cell-based bioassays. MS peptide mapping revealed stress-dependent oxidation, deamidation and isomerization with mAb-specific susceptibilities, while NMR experiments such as 1D 1H diffusion-filtered (1D DF), 1D 1H excitation sculpting with perfect echo (1D ESPE) and 2D 1H-13C Heteronuclear Multiple-Quantum Correlation (2D XL-AFHMQC), clearly distinguished samples subjected to different types of stress. Specifically, multivariate statistical analysis performed on 1D DF NMR spectra correlated quantitatively with biological activity and 2D XL-AFHMQC NMR spectra revealed some specific signatures of thermal and light stress. Notably, rapid 1D ESPE experiments, requiring only minutes of acquisition time, selectively detected NMR signals from mobile side-chain resonances from tyrosine, histidine, and asparagine/glutamine residues, together with formulation-derived histidine signals, that acted as intrinsic reporters of stress-induced molecular perturbations. Together, these results establish that naturally mobile molecular reporters captured by NMR provide a rapid, non-destructive readout of antibody integrity, linking structural perturbations, chemical modifications, and biological activity.

PMID 43046445
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab